The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): ##STR00001## R.sup.2 is selected from the group consisting of --C.sub.1-8alkyl-Z, --C.sub.2-8alkenyl-Z and --C.sub.2-8alkynyl-Z; wherein the --C.sub.1-8alkyl-Z, --C.sub.2-8alkenyl-Z and --C.sub.2-8alkynyl-Z and Z is a 5 to 6 member aromatic monocyclic heteroaryl ring having from 2 to 4 heteroatoms. These compounds are useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.